Pharma Focus Asia

Zika Virus Replicons For Drug Discovery

Authors: Xuping Xie, Jing Zou, Chao Shan, Yujiao Yang, Dieudonné Buh Kum, Kai Dallmeier, Johan Neyts, Pei-Yong Shi


The current epidemic of Zika virus (ZIKV) has underscored the urgency to establish experimental systems for studying viral replication and pathogenesis, and countermeasure development. Here we report two ZIKV replicon systems: a luciferase replicon that can differentiate between viral translation and RNA synthesis; and a stable luciferase replicon carrying cell line that can be used to screen and characterize inhibitors of viral replication. The transient replicon was used to evaluate the effect of an NS5 polymerase mutation on viral RNA synthesis and to analyze a known ZIKV inhibitor. The replicon cell line was developed into a 96-well format for antiviral testing. Compare with virus infection-based assay, the replicon cell line allows antiviral screening without using infectious virus. Collectively, the replicon systems have provided critical tools for both basic and translational research.


Zika; Drug discovery; Replicon; Flavivirus

Citation: Xuping Xie, Jing Zou, Chao Shan, Yujiao Yang, Dieudonné Buh Kum, Kai Dallmeier, Johan Neyts, Pei-Yong Shi Zika Virus Replicons For Drug Discovery

Received: 31 August 2016, Revised: 9 September 2016, Accepted: 13 September 2016, Available online: 14 September 2016

Copyright: © 2016 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (

Funding Sources

X.X. was awarded with a postdoctoral fellowship from Novartis Institutes for BioMedical Research. P.Y.S. was supported by University of Texas Medical Branch startup award, University of Texas STARs Award, and NIH grant R01AI087856.

Conflict of Interest Statement

The authors have no conflict of interest in this study.

Author Contributions

X.X., J.Z., S.C., Y.Y., and D.B.K. performed experiments and data analysis. X.X, K.D., J.N., and P.Y.S. interpreted the results. X.X., K.D., J.N., and P.Y.S. wrote the manuscript.


We thank our lab members and colleagues at University of Texas Medical Branch at Galveston for helpful discussions during the course of this study.

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024